Acrux Limited (AU:ACR) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Acrux Limited has achieved FDA approval for its sixth topical ANDA, a generic version of Nitroglycerin Ointment, aimed at treating pain from chronic anal fissures. This approval marks another milestone for Acrux’s R&D team, highlighting their ability to develop and commercialize topical pharmaceutical products. With an annual market exceeding $23 million in sales, Acrux’s new product is set to compete in the growing US market.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Walmart’s (NYSE:WMT) $2.3 Billion Deal With Vizio Closes
- Ford (NYSE:F) Electric Vehicle Sales Hit New Record
- Analysts Revise Their Outlook for Intel (NASDAQ:INTC)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
